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Abstract: The effect of Pgp induction in rats by pregnenolone 16α-carbonitrile (PCN)  
(3 days, 35 mg/kg/d, p.o.) on digoxin pharmacokinetics and intestinal transport has been 
assessed. After intravenous or oral digoxin dosing the arterial and hepatic portal vein (oral) 
AUC(0-24h) were significantly reduced by PCN pre-treatment. Biliary digoxin clearance 
increased 2-fold following PCN treatment. PCN significantly increased net digoxin 
secretion (2.05- and 4.5-fold respectively) in ileum and colon but not in duodenum or 
jejunum. This increased secretion correlated with increased Pgp protein expression in ileum 
and colon. Both intestinal and biliary excretion therefore contribute to altered digoxin 
disposition following PCN. 
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1. Introduction  
The oral absorption and disposition of digoxin is markedly dependent upon the interaction it has 
with the ATP-dependent export pump P-glycoprotein (Pgp, ABCB1). Numerous in vitro systems have 
been used to investigate the secretory transport of digoxin by Pgp [1,2]. Because digoxin displays a 
very narrow therapeutic index (0.5-0.8 ng.ml
-1
; [3]), changes in intestinal secretory transport could 
significantly impact on efficacy or result in toxicity. Known drug-drug interactions (DDIs) effecting 
digoxin therapy have been highlighted by previous studies [4,5]. In man, Drescher et al. [5], using 
segmental in vivo perfusion of jejunum, have shown direct luminal secretion of intravenously 
administered digoxin sensitive to the P-glycoprotein inhibitor quinidine. Bile elimination of digoxin 
was, however, double that seen in the jejunum [5]. Conversely, digoxin absorption from the 
segmentally perfused intestinal lumen was increased by quinidine [6], showing that P-glycoprotein 
limits xenobiotic uptake. In addition to direct interactions with Pgp that impact on digoxin absorption, 
indirect DDIs have been observed involving nuclear receptor regulatory pathways. Pgp intestinal 
expression is not static but dynamically regulated by the pregnane X receptor (PXR) in human and 
rodent intestine. In man rifampacin treatment increased biliary digoxin excretion but did not 
significantly alter digoxin secretion across perfused jejunum [5]. Rat PXR does not respond to 
rifampacin [7] but pregnenolone 16α-carbonitrile (PCN) is used as an effective rodent-PXR activator 
[8]. In this way, Pgp induction has been confirmed in rat intestine.  
There appears to be a gradient of Pgp expression along the gut; in the rat intestine levels increase 
towards the colon [9-11]. The intestinal expression profile of Pgp is the inverse of the major Phase I 
metabolising enzyme, CYP3A4, which shows higher levels in the proximal regions of the gut [11]. 
Although this constitutive expression of Pgp has been shown to increase along the rat intestinal tract, it 
is not known whether PXR-mediated induction causes differential changes in functional Pgp 
expression in the various regions of the gut or whether the relative degree of Pgp induction is 
conserved throughout its entire length.  
In the context of the whole animal, it remains unclear as to the impact of increased intestinal 
expression of Pgp on digoxin pharmacokinetics. In the rat, digoxin pharmacokinetics are complicated 
by Cyp3a4-mediated hepatic metabolism, although previous studies have indicated that intestinal 
metabolism plays an insignificant role in digoxin disposition [12]. In the present study, both 
intravenous and oral digoxin pharmacokinetics following enterally adiministered PCN treatment have 
been investigated. Hepatic portal vein sampling provides a more direct assessment of the effects of 
intestinal expression on absorption. Furthermore the role of hepatic uptake and biliary excretion of 
digoxin in man [5] implies that enterohepatic circulation of digoxin will occur. The use of bile-
cannulated animals therefore allows the direct determination of the effects of PCN pre-treatment on 
biliary excretion to be determined. 
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The overall study aims were therefore to investigate how p.o PCN activation of PXR impacts on 
digoxin pharmacokinetics, intestinal Pgp levels and digoxin absorption.  
2. Experimental Section 
2.1. Animals 
Male Sprague-Dawley rats (Harlan, Netherlands), aged approximately 100 days and weighing 250-
400 g, were used in the experiments. Animal dosing and surgical/anaesthetic procedures were 
performed in accordance with Swedish law and ethical guidelines described in the Principles of 
Laboratory Animal Care (NIH publication #85-23, revised 1985). 
For PCN pre-treatment, rats were dosed once daily for three days prior to experiments. PCN was 
given by gavage at a dose of 35 mg/kg, suspended in a vehicle of 0.1% (w/v) agarose/ water at 
5 ml/kg. Bauer et al. [13] have shown that PCN increases Pgp expression in rat liver and brain using  
3 daily divided doses at 10 and 25 mg/kg ip. Control rats were dosed with 5 ml/kg vehicle alone for the 
same time period. 
For all surgical procedures, rats were anaesthetised using inhaled isofluorane (induction 5%,  
2 L/min and thereafter 3%, 0.7 L/min) and placed on a heated table to maintain body temperature. To 
facilitate arterial blood sampling for pharmacokinetic measurements, all rats used in the in vivo studies 
had a polythene cannula (PP25) inserted into the left common carotid artery via a small incision made 
in the chest. The free end of the cannula was stoppered and passed subcutaneously out through a small 
incision in the dorsal nape of the neck, allowing quick access to the cannula during the experiments. 
For rats in which intravenous administration was required, the right external jugular vein was 
cannulated with polyethylene (PE50) tubing, which was again passed through the dorsal skin of the 
neck. In the bile collection experiments, both the left carotid artery and common bile duct were 
cannulated. To allow bile flow until the experiment a catheter was also inserted into the duodenum and 
it was also passed through the dorsal skin of the neck and connected to the bile catheter. In the portal 
vein studies, both the left carotid artery and the portal vein were cannulated. 
2.2. Pharmacokinetics studies 
For pharmacokinetic experiments, cannulae allowed both blood and bile sampling and did not 
require the animals to be anaesthetised during the procedure. Animals were dosed either intravenously 
with 2 MBq/kg of a [
3
H]-digoxin saline bolus (1 ml/kg over 20 seconds followed by a 150 l flush of 
saline/ heparin) or orally at 4 MBq/kg (2 ml/kg by gavage). Arterial blood samples (150 µl) were taken 
at the appropriate time points from the carotid artery cannulae and the volume was replaced by a 
saline/heparin flush. Where appropriate, simultaneous samples were taken via the portal vein cannula. 
Bile sampling was done by allowing each bile cannula to drain continually into a glass vial throughout 
the duration of the experiment; at the appropriate sampling time point each was replaced by a fresh 
one. Blood samples were centrifuged, and 75 µl volumes of plasma or bile were counted for 
3
H activity 
on a scintillation counter (Wallac 1414, Finland) following correction for quench using tritiated 
standards prepared in rat plasma and bile. Rats were sacrificed by anaesthetic overdose following 
completion of the experiments. 
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2.3. Ussing Chamber studies  
Rats were anaesthetised as described in the ‘Animals’ section. Following abdominal incisions, 
intestinal lumens were occluded by thin cotton thread proximal to the sections of tissue taken from 
duodenum, jejunum, ileum and colon. Sections were washed with 2 x 20 ml of ice-cold Krebs’-
bicarbonate Ringer (KBR) solution (pH 7.4) (108.0mM NaCl, 4.7mM KCl, 0.6mM Na2HPO4/KH2PO4, 
16mM NaHCO3, 1.2 mM MgSO4, 1.2 mM CaCl2, 4.9 mM Na-Pyruvate, 5.4mM Fumarate, 4.9mM L-
Glutamate, 11.5mM Glucose) to remove chyme and faecal matter. The segments were placed in a 
chamber containing ice-cold KBR perfused with carbogen for 30 minutes. Removal by dissection of 
the serosal layer of the duodenal, jejunal and ileal sections and the serosa and muscularis externa of the 
colonic sections was performed with the aid of a stereo microscope (Wild M8) and a light source 
(Schott KL 1500).  
Intestinal segments were mounted as flat sheets in a modified Ussing chamber (Department of 
Pharmaceutical Technical Support at Astra Hässle AB). The exposed tissue surface area was 1.14 cm
2
. 
Agar bridges (6% Agar-Agar in 0.9% NaCl) were used to connect reference electrodes (calomel for 
Potential Difference, PD, (mV) measurements and Ag/AgCl for current passage). Asymmetry in the 
PD arising from the calomel/agar bridges were zeroed prior to tissue mounting. Likewise correction for 
voltage drop across the series fluid resistance upon current passage was made in assembled chambers 
prior to tissue mounting.  
After 30-40 minutes’ equilibration at 37
o
C, mean PD and SCC values for duodenum, jejunum and 
ileum of 4.1 ± 0.4, 6.4 ± 0.5, and 6.2 ± 0.5 mV (basal solution electropositive) and 161 ± 11, 271 ± 23, 
and 202 ± 21 A/cm2 were recorded. A larger mean value of 8.1 ± 0.9 mV (basal solution 
electropositive) but a SCC of 94 ± 13 A/cm2 for colon was observed. These values are entirely 
comparable with other studies [14].  
The KBR in “donor” or “receiver” wells was replaced with 10 ml of test solution containing donor 
tracers of [
3
H]-digoxin and [
14
C]-mannitol or KBR to initiate the experiment. At specific timepoints, 
samples were remover and mixed with 5 ml of scintillation cocktail (OptiPhase ‘HiSafe’ 2 Liquid 
Scintillation Cocktail, Wallac) and the [
3
H] and [
14
C] activities determined using a liquid scintillation 
counter (Wallac, Finland). 
The apparent permeability coefficients (Papp; Pa-b & Pb-a) were calculated using the equations 
below: 
Ja-b = (Db * M)/ (Dt *s* SA);     Pa-b = Ja-b / Ca (1) 
Jb-a = (Da * M)/ (Dt *s * SA);     Pb-a = Jb-a / Cb (2) 
where Da and Db represent the activity (in dpm) transported to the apical and basal receiver 
compartments, respectively. Dt is the total activity present in the donor compartment, M is the total 
number of moles of substrate present in the donor compartment, s is the time in seconds, SA represents 
the area of tissue exposed to the solution (1.14 cm
2
) and Ca and Cb represent the concentration of the 
substrate in the donor compartment in moles/cm
3
. Pa-b, b-a or Papp is expressed in cm/s. 
The permeability of the inert sugar-alcohol mannitol as a paracellular flux marker [2,15] was 
determined by addition of the radiolabelled [
14
C]-mannitol to the pre-prepared donor solutions.  
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2.4. Western transfer 
Protein was extracted from excised sections of rat intestinal mucosa. Using a 2 mL glass 
homogeniser, tissue was broken down in a lysis buffer consisting of 250 μM EDTA (pH 8.0), 250 μM 
EGTA (pH 8.0), 320 μM sucrose, 500 μM Tris (pH 7.6), 1% Triton X (v/v) and distilled water up to a 
volume of 10 mL, with the addition of 1 proprietary Complete Protease Inhibitor Cocktail tablet 
(Roche, Cat No. 04693116001). Proteins were separated on 8% SDS-polyacrylamide gels and 
transferred onto PVDF membranes (millipore) overnight. Membranes were briefly washed with TBS-T 
(Tris-buffered saline and 0.1% Tween 20, pH 7.6) and blocked in 3% non-fat dried milk in TBS-T 
buffer. Membranes were probed overnight at 4 °C with the mouse monoclonal antibody C219 
(Calbiochem), directed against an internal epitope of human MDR1 cross-reacting with rodent Pgp. 
The antibody was diluted 1:50 in TBS-T buffer. Following further washing, membranes were 
incubated with HRP-labeled anti-mouse IgG (AbCam) and bands detected with the pico-
chemiluminescence substrate (Pierce) following manufacturers’ instructions. 
Equal loading was confirmed by re-probing blotted membrane for β-actin. Membranes were 
stripped and washed with TBS-T. They were probed with the mouse anti-human β-actin antibody 
(AbCam) diluted 1:100 in 5% milk (in TBS-T buffer). Secondary staining and chemiluminescence was 
performed as described above.  
2.5. Materials 
Buffer components and PCN were supplied by Sigma. [
3
H]-digoxin (specific activity 23.5 Ci/mmol) 
and [
14
C]-mannitol (specific activity 30 Ci/mmol) were bought from PerkinElmer. The anti-MDR1 
mouse monoclonal antibody C219 was purchased from Calbiochem (Merck Chemicals Ltd, 
Nottingham, UK). The anti-mouse HRP conjugates from AbCam (Cambridge, UK). 
2.6. Pharmacokinetic calculations 
Pharmacokinetic evaluation was performed using WinNonlin Enterprise, version 4.1 (Pharsight 
Corporation, California, USA), and data are expressed as mean ± SEM. Biliary clearance (CLbile in 
L/h/kg) at the final time point (8 h) was calculated as follows: CLbile = cumulative amount of [
3
H]-
digoxin in bile (nmol)/portal vein AUC(0-8h) (nmol/h/L)/body weight (kg). 
2.7. Statistics 
All data are expressed as mean ± standard error of the mean (SEM) with n representing the number 
of replicates in each experiment. Statistical analysis was performed using One-Way ANOVA with 
Bonferroni’s post-tests for multiple comparisons. Unpaired Student’s T-tests were used to compare 
individual pairs of experiments. All analysis performed using Prism 4 (Graphpad InStat, San Diego, 
California, USA). Statistical significance was reported at P < 0.05. 
Pharmaceutics 2010, 2              
    
 
66
3. Results and Discussion 
3.1. The impact of PCN-treatment on plasma [3H]-digoxin concentrations following oral and IV 
administration 
Figure 1 shows that PCN pre-treatment substantially alters the pharmacokinetic plasma profiles of 
[
3
H]-digoxin after intravenous (IV) (2.3 nmol.kg
-1
) or oral (PO) (4.6 nmol.kg
-1
) dosing. Following IV 
administration (Figure 1a) the concentration of [
3
H]-digoxin remaining in blood plasma was reduced at 
all time points in PCN-dosed rats in comparison to control animals. The IV and oral [
3
H]-digoxin 
AUC(0-24h) for control and PCN-treated animals are shown in Table 1.  
Table 1. [
3
H]-digoxin arterial and portal vein AUC in control and PCN-treated rats. 
Significant difference as indicated by Student’s T-test *** p < 0.001, * p < 0.05. 
Arterial AUC (nmol.hr
-1
/L) Portal AUC (nmol.hr
-1
/L) 
Dosing Control PCN Control PCN 
IV 3.55 ± 0.09 1.90 ± 0.03***  -  - 
Oral 4.95 ± 0.38 2.67 ± 0.59* 3.81 ± 0.09 2.75 ± 0.09* 
 
Significant reductions in IV and oral [
3
H]-digoxin AUC(0-24h) (p < 0.001 & p < 0.05, respectively) 
are evident for PCN-treated animals in comparison to controls (Table 1). Following oral dosing in 
control animals, there was an initial rise in plasma [
3
H]-digoxin between 5 minutes (0.53 ± 0.09 nM,  
n = 4) and 15 minutes (0.75 ± 0.10 nM, n = 4), indicating a period of rapid intestinal uptake into the 
systemic circulation (Figure 1b). In the PCN-dosed animals the concentration of [
3
H]-digoxin entering 
the circulation is greatly reduced (Figure 1 b). This results in a reduced AUC(0-24h) in the PCN-treated 
animals (p < 0.05 versus controls, Table 1) and a reduced Cmax from 0.77 ± 0.09 nM, n = 4 in controls 
to 0.27 ± 0.02 nM, n = 4 (p < 0.005). 
3.2. Hepatic portal vein [3H]-digoxin activities and biliary [3H]-digoxin secretion  
In order to assess the contribution of hepatic clearance and biliary excretion of [
3
H]-digoxin/digoxin 
metabolites to the plasma profile following oral absorption, total [
3
H] activities in hepatic portal vein, 
arterial plasma and in bile were determined after oral [
3
H]-digoxin dosing (Figures 2 and 3). Figure 2a 
confirms the initial observation that PCN pre-treatment produces a significant reduction in systemic 
arterial plasma [
3
H] concentrations; the AUC(0-24h) in controls was 3.16 ± 0.27 nmol.hr
-1
/L (n = 5), 
which decreased to 2.04 ± 0.15 nmol.hr
-1
/L (n = 6) in PCN-treated animals. Figure 2b shows that in 
the same animals, PCN treatment also reduced portal vein plasma AUC(0-24h). Portal vein plasma  
AUC(0-24h) values are shown in Table 1, indicating a significant reduction in PCN-treated plasma 
concentration as compared to controls (n = 6&5 respectively; p < 0.02). However, portal vein Cmax 
shows a non-significant reduction from 0.93 ± 0.17 nM, n = 5 in controls to 0.62 ± 0.06 nM, n = 6 in 
PCN treated animals (p < 0.1, n.s.). A significant hepatic clearance of [
3
H]-digoxin is indicated by the 
difference in Cmax between control animals for portal vein and arterial plasma samples (0.93 ± 0.17 
nM, to 0.44 ± 0.05 nM, n = 5 p < 0.05) and for PCN-treated animals (0.62 ± 0.06 nM, to 0.29 ± 0.04 
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nM, n = 6 p < 0.001). This data is therefore consistent with both a reduced intestinal absorption of 
digoxin, but also a component of enhanced hepatic extraction in the whole animal response to PCN 
treatment. Whereas PCN treatment decreases portal vein AUC(0-24h) by 28%, arterial AUC(0-24h) is 
reduced by 35%. Hepatic extraction reduces arterial [
3
H]-digoxin AUC(0-24h) by 17% in control animals 
compared to 26% in PCN pre-treated rats. 
Conventionally the presence of Pgp in the apical membrane of the intestine is thought to limit the 
epithelial absorption of Pgp substrates below the levels expected from the physicochemical properties 
of the compound alone (mainly lipophilicity). Increases in Pgp would therefore further limit intestinal 
absorptive permeability, so reducing circulating plasma levels. Hepatic portal vein blood digoxin 
concentrations are reduced at all but the initial time points after oral dosing, with a significant 
reduction in the AUC(0-24h) as well as the Cmax, suggesting that in vivo a reduction in intestinal 
absorption must occur. Although digoxin is reported to be a substrate for rodent cyp3a4, studies have 
concluded that rat intestinal digoxin metabolism was negligible [16], with the formation of digoxigenin 
bis-digitoxoside (Dg2) at <1% and levels of mono-digoxitoxoside (Dg1) and digoxigenin (DG0) even 
lower or undetectable [12]. This metabolic profile was also found to be unaltered following PCN 
treatment [12]. Accordingly it is reasonable to suggest that the reduced levels of digoxin in the hepatic 
portal vein are the result of an increased functional Pgp expression in the intestine. 
A hepatic component was confirmed by measurement of bile flow and cumulative [
3
H]-digoxin 
secretion via bile (Figure 3). Whereas bile flow is unaltered over the 8 hour time-course by PCN pre-
treatment (Figure 3b), [
3
H]-digoxin excretion to bile is increased; at 2 hours 0.25 ± 0.05, n = 6 of the 
[
3
H]-digoxin dose is excreted into bile in the PCN-treated rats compared to controls, where just 
0.11 ± 0.01, n = 6 (p < 0.05) of the dose is excreted. Furthermore, the calculated CLbile at 8 h rose from 
0.69 L/h/kg in controls to 1.39 L/h/kg in the PCN-treated rats, a 2-fold increase. 
Excretion into bile is significantly increased in the PCN treated animals at 2 hours. How is 
excretory transport into bile increased? Both Pgp and PXR are present in hepatocytes [17] and 
induction of canalicular Pgp could represent a mechanism for increased digoxin transport. However, 
the liver-specific oatp1a4 (old nomenclature oatp2, gene Slco1A4, previously termed Slc21A5) is a 
high affinity digoxin transporter which impacts on digoxin disposition [15,16] . Oatp1a4 is present on 
the sinusoidal membrane of hepatocytes and numerous studies have reported PXR-mediated induction 
of oatp1a4 in response to xenobiotics, including PCN [19,20]. An increase in hepatic sinusoidal 
oatp1a4 expression, coupled to similar increases in canalicular Pgp levels would explain increased 
biliary clearance. Increased digoxin metabolism is also possible, as PCN is also known to induce cyp3a 
expression [12] with hepatic metabolism by cyp3a comprising an estimated 60% of the dose [21-23]. 
Potential metabolism must therefore be taken into account when assessing whole body digoxin 
disposition in rat. Our attempts at separating metabolites from total [
3
H]-digoxin were unsuccessful. A 
similar increase in biliary secretion of ouabain, which is not metabolised, was previously observed in 
PCN pre-treated rats [24]. 
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Figure 1. Time-dependence of [
3
H]-digoxin plasma concentrations in control and PCN 
treated rats following intravenous and oral administration (a) Arterial plasma 
concentrations of [
3
H]-digoxin in rats following IV administration at 2.3 nmol.kg-1 or  
(b) oral administration at 4.6 nmol.kg-1 for control (■) and PCN (○) dosed animals, treated 
for 72 hours prior to the experiment. Data are mean ± SEM of n = 3 (IV) and n = 4 (PO) 
animals. 
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Figure 2. Time-dependence of [
3
H]-digoxin plasma concentrations in control and PCN 
treated rats following oral administration in (a) arterial plasma and (b) portal vein plasma 
for control (■) and PCN (○) dosed animals, treated for 72 hours prior to the experiment. 
Data are mean ± SEM of n = 5 control or 6 PCN-treated animals. 
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Figure 3. Excretion of digoxin into bile in control and PCN-dosed rats. (a) Cumulative 
dose (%) of [
3
H]-digoxin excreted into bile following oral administration (4.6 nmol.kg
-1
). 
Results indicate % dose in control (■) and PCN (○) dosed animals, treated for 72 hours 
prior to the experiment. Data are mean ± SEM of n = 5 (control) and n = 6 (PCN) animals. 
(b) shows the bile flow during 8 hours sampling. 
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3.3. [3H]-Digoxin transport in excised intestinal sections 
From the pharmacokinetic profiles, it is apparent that intestinal digoxin absorption is substantially 
altered following PCN treatment. In order to assess the impact of intestinal transport on the 
pharmacokinetic plasma profiles, transepithelial [
3
H]-digoxin fluxes were measured across isolated 
intestinal sections, mounted in modified Ussing chambers (Figure 4). [
3
H]-Digoxin transport was 
determined to be greater in the basal-to-apical (Pb-a) than apical-to-basal (Pa-b) direction across all 
excised tissue sections (duodenum, jejunum, ileum and colon; Figure 4). Under control conditions a 
net [
3
H]-digoxin secretion (expressed as permeability Pnet=Jnet/Cdigoxin) of 4.88 ± 1.36 cm.s
-1 
(x 10
-6
)  
(n = 6) for duodenum, 4.20 ± 1.75 cm.s-1 (x 10-6) (n = 12) for jejunum, 5.79 ± 1.60 cm.s-1 (x 10-6)  
(n = 9) for ileum and 7.52 ± 3.33 cm.s-1 (x 10-6) (n = 6) for the colon was observed.  
The passive permeability of radiolabelled [
14
C]-mannitol was measured concurrently with [
3
H]-
digoxin flux as a measure of the paracellular flux component and therefore the amount of ‘leak’ 
inherent within each section of intestine. Mannitol permeability was significantly different only in the 
colon (2.18 ± 0.40 cm.s
-1
, n = 20) compared to the other intestinal segments, e.g., the jejunum  
(6.02 ± 0.76 cm.s
-1
, n = 43). This difference correlates with a greater electrical resistance for colon 
compared to jejunum (97.9  13.4 Ω.cm2, n = 12 compared to 28.6  1.9 Ω.cm2, n = 43 p < 0.01).  
There were no significant changes in PD or SCC in any section of the intestine following PCN-
dosing. Also for the duodenum, jejunum and ileum, PCN treatment displayed no effect on trans-
intestinal resistance recordings. The resistance across sections of colon excised from PCN-dosed 
animals (127.6  5.9 Ω.cm-2, n = 9) were slightly increased compared to controls (97.9  13.4 Ω.cm-2, 
n = 12) p < 0.05. In addition there were also no significant changes in mannitol permeability between 
controls and PCN-treated duodenal, jejunal and colonic tissue segments. Overall it is apparent that 
PCN-dosing of animals is without effect on either tissue integrity or ion transport of the four intestinal 
segments used in this study. 
Figure 4a and 4b show that PCN pre-treatment does not significantly alter duodenal or jejunal net 
[
3
H]-digoxin permeability. In the ileum however, there were significant increases in both Pb-a  
(7.43 ± 1.95 cm.s
-1 
(x 10
-6
), n = 9 to 12.98 ± 1.51 cm.s-1 (x 10-6), n = 7, p < 0.05) and Pnet (5.79 ± 1.60 
cm.s
-1 
(x 10
-6
), n = 9 to 11.89 ± 1.48 cm.s-1 (x 10-6), n = 7, p < 0.05) (Figure 4c). This represents a 
1.75-fold increase in Pb-a and a 2.05-fold increase in Pnet, suggesting an increase in the functional 
activity of the secretory efflux transporter Pgp. A larger increase in the basal-to-apical and net 
permeability of [
3
H]-digoxin was seen in the excised colon sections, with Pb-a significantly increasing 
(p < 0.01) from 9.25 ± 3.77 cm.s
-1 
(x 10
-6
) (n = 6), to 35.93 ± 4.47 cm.s-1 (x 10-6) (n = 4), a 3.9-fold 
increase (Figure 4d). Net secretory flux also displayed the same pattern with a significant increase  
(p < 0.01) of 4.5-fold, from 7.52 ± 3.33 cm.s
-1 
(x 10
-6
) (n = 6), to 34.11 ± 4.25 cm.s-1 (x 10-6) (n = 4) 
(Figure 4d). The larger increases in colonic [
3
H]-digoxin secretion following PCN treatment suggest a 
greater capacity for increasing Pgp expression and activity in the distal GI tract. 
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Figure 4. Segmental changes in intestinal bi-directional [3H]-digoxin flux in PCN-dosed 
rats. Transintestinal [3H]-digoxin permeability across excised sections of intestine 
mounted in modified Ussing chambers. Permeability was determined in both the apical-to-
basal (Pa-b) and basal-to-apical (Pb-a) directions. Rats were dosed for 72 hours with an 
agarose vehicle control or PCN (35 mg.kg-1) prior to tissue excision. (a) duodenum, Data 
is mean ± SEM of n = 6 (Control) and n = 5 (PCN) tissue sections (b) jejunum, Data is 
mean ± SEM of n = 12 (Control) and n = 9 (PCN) tissue sections (c) ileum, Data is mean 
± SEM of n = 9 (Control) and n = 7 (PCN) tissue sections (d) colon Data is mean ± SEM 
of n = 6 (Control) and n = 4 (PCN) tissue sections. * P < 0.05, significantly different from 
control values. 
 
 
Pgp activity is conventionally thought to reduce the apparent absorptive permeability of substrates 
when expressed in model cell-lines and in intestinal tissues [5,25]. This is most evident following Pgp 
inhibition (e.g. by verapamil), with an increase in the absorptive permeability (Pa-b) of a concurrently 
measured substrate. Under basal conditions, [
3
H]-digoxin Pa-b values were 1.05 ± 0.22 cm.s
-1
 (x 10
-6
) 
(n = 6) for duodenum, 2.01 ± 0.80 cm.s-1 (x 10-6) (n = 12) for jejunum, 1.64 ± 0.61 cm.s-1 (x 10-6)  
(n = 9) for ileum and 1.73 ± 0.46 cm.s-1 (x 10-6) (n = 6) for colon. Following PCN treatment, no 
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significant changes in [
3
H]-digoxin Pa-b were observed in any of the four sections (duodenum - 1.27 ± 
0.51 cm.s
-1 
(x 10
-6
), n = 5, jejunum - 1.74 ± 0.34 cm.s-1 (x 10-6), n = 10, ileum - 1.08 ± 0.09 cm.s-1 (x 
10
-6
), n = 8, colon – 1.48 ± 0.42 cm.s-1 (x 10-6), n = 5, P > 0.1). The lack of effect on Pa-b by the 
increased Pgp activity in colon and ileum mounted in Ussing chambers may indicate that in vitro an 
additional pathway for absorption of [
3
H]-digoxin is introduced by “edge effects” increasing 
“paracellular” diffusion above in vivo levels so obscuring any reduction due to Pgp.  
At the present time, there is little data on the regional expression of PXR in the intestine. PXR 
mRNA and protein expression is limited in proximal rat intestine relative to liver [26]. Although PXR-
mediated increases in Pgp expression in human and rat intestine have been reported [12,27], these 
studies do not address Pgp increases along the length of the gut. As Pgp expression is reported to 
increase aborally along the intestine [9,28,29], Pgp-mediated digoxin efflux would be expected to be 
higher in the ileal and colonic segments. The present study has shown that for control rats there was 
only a limited increase in the magnitude of digoxin secretion (permeability) from duodenum to colon.  
Direct measurements of absorptive digoxin permeability (Pa-b) in vitro after PCN treatment in all 
intestinal segments do not show such a reduction in Pa-b, despite the increased net secretion of digoxin 
that is observed in ileum and colon. Experiments in rat brush-border intestinal vesicles have suggested 
that digoxin uptake is mediated by a proton-dependent carrier [30] but an additional route in vitro via a 
paracellular pathway in part arising from tissue damage may exist. 
3.4. P-glycoprotein(Pgp) expression in rat intestinal tissue segments  
Figure 5a shows the Western blot analysis for the expression of Pgp using the monoclonal antibody, 
C219. As Pgp expression levels were low in proximal intestine, chemiluminescent exposures of  
5 minutes were required for duodenal and jejunal samples, whereas only a 10 second exposure was 
required to detect Pgp in PCN-treated ileum and colon samples. Prominent bands at approximately 
170kD, representing the reported size for P-glycoprotein are evident for control samples; note that for 
ileal and colonic control samples, a 10 second exposure time is not sufficient to detect protein, 
however, longer exposure times would have led to saturation of the signal detected in the PCN-treated 
samples. In control samples of duodenum and jejunum there is marked variability between animals 
(Figure 5a). C219-stained membranes were stripped and re-probed for the expression of the 
constitutively expressed house-keeping gene, β-actin. Densitometric analysis of digitised images 
allowed expression of Pgp to be normalised to β-actin expression (Figure 5b). This data shows that 
whereas no significant change in the Pgp expression levels occurs in either duodenal or jejunal tissue 
despite the increase in mean values, both the ileum and colon display significant increases in Pgp 
protein levels following exposure to PCN (increases of 1.3-fold in the ileum and 2.9-fold in the colon; 
P < 0.05).  
Western blot analysis for control rats is therefore similar to the permeability (secretion) data in that 
a marginal, but non-significant increase in Pgp protein expression is seen in the distal intestine. Since 
Pgp expression is dynamic and dependent on dietary and environmental factors, the lack of a marked 
aboral gradient in either protein expression or digoxin permeability may represent the strict diet of 
laboratory rats not exposed to a more challenging and variable “scavenger” diet.  
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Figure 5. Western blot analysis of MDR1 and β-actin protein expression in excised 
sections of intestine from control and PCN-dosed rats (a) Samples of intestinal protein 
extracted from rat duodenum, jejunum, ileum (100 μg) and colon (50 μg) were separated 
by gel electrophoresis and probed for the presence of P-glycoprotein with the mouse-
monoclonal antibody C219. Duodenal and jejunal blots were exposed for 5 minutes, ileal 
and colonic blots were exposed for 10 seconds. P-glycoprotein bands were visible at 
approximately 170 kDa. Blots were stripped and re-probed for the presence of β-actin with 
a cross-species polyclonal antibody (Abcam). β-actin bands were visible at approximately 
37 kDa. (b) Densitometric analysis of P-glycoprotein blots indicating band pixel density 
relative to β-actin expression level. Data are mean ± SEM of n = 4 protein samples.  
* P < 0.05, significantly different from control values. 
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Although there was a lack of variation in regional Pgp protein expression or function digoxin efflux 
in control animals, the present data now shows that Pgp induction potential increases aborally 
following 3 days PCN treatment. Net secretory digoxin transport is significantly increased in both ileal 
and colonic regions, with the greatest increase observed in the large intestine. This increase is matched 
to an increase in protein expression, with Western blot analysis indicating significant increases in Pgp 
protein relative to -actin in both the ileum and colon, but with no change in the duodenum and 
jejunum. For the rat, secretory intestinal transport is likely limited to that mediated by Pgp [2]. That 
Pgp is preferentially increased in the distal intestine also implies a functional linkage between PXR 
and Pgp expression restricted to the distal intestine. Transit time in the upper small intestine is rapid, 
which is in contrast to the colonic regions where transit time is prolonged to allow for microbial 
fermentation and faecal dehydration by water re-absorption [31,32]. The greater increase in Pgp 
expression may result from an increase in both exposure time and concentration of xenobiotics, in this 
case PCN. Likewise, due to the reduced transit rate and increased exposure to xenobiotics, it is 
possible that PXR expression may be higher in colon to allow a greater capacity for increasing the 
physiological barrier (Pgp and CYP3A4 expression). 
4. Conclusions 
The current data has indicated that PCN treatment has a substantial impact on digoxin 
pharmacokinetics in the rat. Intestinal absorption is significantly reduced as a result of up-regulated 
Pgp expression. In vitro Ussing chamber data shows that the distal small intestine and colon have a 
greater capacity for increasing Pgp levels in response to PXR activation, which may impact on digoxin 
enterohepatic recirculation. Hepatic extraction is also seen to increase, partially as a result of increased 
biliary excretion. Our data therefore indicates a likely synergistic role for both intestinal secretion and 
biliary excretion in the altered disposition of digoxin in rats. 
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